GlassScriptPhysician profile
Baili Rose Bailey
NPI 1760200414
$1,406.94
in general payments reported to CMS, 2019-2025
24 companies · $1,407 in 2025
The $1,407 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,407.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,406.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $269.06 | 2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $153.30 | 2025 | Airsupra, Farxiga |
| Axsome Therapeutics, INC. | $116.79 | 2025 | Auvelity, Sunosi |
| Lilly USA, LLC | $115.45 | 2025 | Zepbound, Mounjaro, Jardiance |
| Pfizer INC. | $86.81 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $69.53 | 2025 | |
| Verona Pharma, INC. | $64.99 | 2025 | Ohtuvayre |
| Abbvie INC. | $60.03 | 2025 | |
| Collegium Pharmaceutical, INC. | $56.48 | 2025 | Jornay Pm |
| Insulet Corporation | $53.39 | 2025 | Omnipod |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $50.40 | 2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $47.35 | 2025 | Voquezna |
| Sanofi-Aventis U.S. LLC | $32.88 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.02 | 2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.47 | 2025 | Jardiance |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $24.00 | 2025 | Korlym |
| Dexcom, INC. | $23.30 | 2025 | Dexcom G6 Transmitter |
| Hologic Sales and Service, LLC | $23.10 | 2025 | Thinprep 2000 Processor, Aptima |
| Vertex Pharmaceuticals Incorporated | $19.41 | 2025 | |
| Bausch Health US, LLC | $17.06 | 2025 | Wellbutrin, Aplenzin |
| Almatica Pharma LLC | $16.81 | 2025 | Loreev Xr |
| Vanda Pharmaceuticals INC. | $16.08 | 2025 | Hetlioz, Fanapt |
| Tolmar, INC. | $14.84 | 2025 | Jatenzo |
| Glaxosmithkline, LLC. | $14.39 | 2025 | Arexvy, Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Baili Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.